MicroRNA-495 suppresses cell proliferation and invasion of hepatocellular carcinoma by directly targeting insulin-like growth factor receptor-1

YING YE1*, JUHUA ZHUANG1*, GUANGDONG WANG2, SAIFEI HE1, SUILIANG ZHANG3, GUOYU WANG1, JING NI1, JIENING WANG1 and WEI XIA1

Departments of 1Nuclear Medicine, 2Research and Development, and 3Oncology, The Seventh People's Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200137, P.R. China

Received July 2, 2017; Accepted November 6, 2017

DOI: 10.3892/etm.2017.5467

Abstract. Hepatocellular carcinoma (HCC) is the fifth most common malignancy and second-most frequent cause of cancer-associated deaths worldwide. Previously, increasing studies report that microRNAs (miRNAs/miRs) are abnormally expressed in various types of human cancers and may participate in the tumourigenesis and tumour development of HCC. miRNA-based targeted therapy is effective against different molecular targets and may increase the sensitisation of cancer cells to therapy by several folds. Therefore, further validation of potentially important miRNAs involved in HCC initiation and progression may provide valuable insights into the treatment of patients with HCC. miR-495 is abnormally expressed in multiple types of human cancers. However, the expression level and roles of miR-495 in HCC have yet to be completely elucidated. In the present study, miR-495 expression was frequently downregulated in HCC tissues and cell lines, and miR-495 expression levels were significantly correlated with tumour size, tumour-node-metastasis (TNM) stage and lymph node metastasis in patients with HCC. Functional assays revealed that miR-495 overexpression inhibited cell proliferation and invasion in HCC. Insulin-like growth factor receptor-1 (IGF1R) was identified as a direct target gene of miR-495 in HCC. IGF1R was upregulated in HCC tissues and negatively correlated with miR-495 expression level. The upregulation of IGF1R rescued the miR-495-induced tumour-suppressive roles in HCC cell proliferation and invasion, and the restored miR-495 expression inactivated the protein kinase B and extracellular regulated protein kinase signalling pathways in HCC. These results provide novel insights into the molecular mechanism underlying HCC progression, and suggest that miR-495 may be investigated as a novel therapeutic target for patients with this disease.

Introduction

Hepatocellular carcinoma (HCC), the fifth-most common malignancy and second-most frequent cause of cancer-related deaths worldwide (1,2), accounts for approximately 780,000 new cases and 745,000 deaths attributed to HCC each year (3). Multiple risk factors, including hepatitis B virus or hepatitis C virus infection, dietary aflatoxin B1 contamination, chronic alcohol abuse and tobacco consumption, lack of dietary antioxidants, arsenic exposure, obesity and non-alcoholic fatty liver disease, involved in HCC formation and progression have been identified (2,4). Chronic infection with hepatitis B virus or hepatitis C virus causes approximately 75% of all HCC cases (5). Although advanced treatments for patients with HCC have been developed, the long-term prognosis for these patients remains poor, and their current 5-year survival rate is approximately 30% (6). In addition, molecular mechanisms underlying HCC development have yet to be fully elucidated (7). Therefore, the molecular mechanisms of HCC initiation and progression should be further investigated to establish novel prognostic biomarkers and therapeutic methods for patients with this disease.

MicroRNAs (miRNAs/miRs), an endogenous group of short (18-25 nucleotides), non-coding and single-stranded RNA molecules, have emerged as a major regulator of tumourigenesis and tumour development (8,9). miRNAs negatively regulate gene expression by typically binding to complementary sequences in 3'-untranslated regions (3'-UTRs) of their target genes and therefore stimulate mRNA degradation or translational inhibition (10). Altered miRNA expression has been described in various types of human malignancies, such as HCC (11), renal cell carcinoma (12), gastric cancer (13) and colorectal cancer (14). miRNA dysregulation has been

Correspondence to: Professor Wei Xia or Professor Jiening Wang, Department of Nuclear Medicine, The Seventh People’s Hospital, Shanghai University of Traditional Chinese Medicine, 358 Datong Road, Pudong, Shanghai 200137, P.R. China
E-mail: xiawei_tcm@163.com
E-mail: doctorwjm@126.com

*Contributed equally

Key words: hepatocellular carcinoma, microRNA-495, proliferation, invasion, insulin-like growth factor receptor-1
Oligonucleotide transfection. Mature miR-495 mimics and miRNA mimics negative control (miR-NC) were chemically synthesized by GeneCopoeia (Shanghai, China). Insulin-like growth factor receptor-1 (IGF1R) overexpression plasmid (pcDNA3.1-IGF1R) and empty plasmid (pcDNA3.1) were acquired from Shanghai GenePharma Co., Ltd. (Shanghai, China). For cell transfection, cells were seeded into 6-well plates at a density of 5x10^4 cells per well. After incubation overnight, cell transfection was performed using Lipofectamine 2000 (Invitrogen Life Technologies, Carlsbad, CA, USA), according to the manufacturer’s instructions.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA was isolated from tissue specimens or cells using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) in accordance with the manufacturer’s instructions. For miR-495 quantification, complementary DNA (cDNA) was synthesized from 1 µg of total RNA using the TaqMan microRNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA). Quantification of miR-495 was performed using a TaqMan microRNA Assay kit (Applied Biosystems; Thermo Fisher Scientific, Inc.). U6 small nuclear RNA was used as an endogenous control. To quantify IGF1R mRNA, corresponding cDNA was obtained from total RNA with a PrimeScript RT Reagent kit (Takara Biotechnology, Co., Ltd., Dalian, China), according to the manufacturer’s protocols. The quantitative PCR was carried out in an Applied Biosystems® 7500 Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.) using SYBR Premix Ex Taq™ kit (Takara Biotechnology, Co., Ltd.), with GAPDH as an internal control. All reactions were performed in triplicate and fold changes were calculated based on relative quantification using the 2^ΔΔCq method (23).

Cell Counting kit-8 (CCK-8) assay. CCK-8 assay was utilized to determine the HCC cell proliferative ability. Transfected cells were collected at 24 h post-transfection, and mechanically dissociated into single cell suspension. Afterwards, transfected cells were seeded into 96-well plates at a density of 3,000 cells/well, and incubated at 37°C with 5% CO_2 for 0, 24, 48, and 72 h. At each time point, CCK-8 assay was performed according to the manufacturer’s protocols. Briefly, each well was treated with 10 µl CCK-8 reagent (Dojindo Molecular Technologies, Inc., Kumamoto, Japan). After incubating at 37°C for additional 2 h, the optical density (OD) at a wavelength of 450 nm was determined using a SpectraMax M5 microplate reader (Molecular Devices LLC, Sunnyvale, CA, USA). Each assay was performed with 5 replications.

Cell invasion assay. Cell invasion assay was performed using Transwell insert chambers (8-µm pore size; Corning, Inc., Corning, NY, USA) coated with Matrigel (BD Biosciences, San Jose, CA, USA). After transfection 48 h, cells were harvested and suspended in FBS-free DMEM. Transfected cells (5x10^4) in 300 µl FBS-free DMEM were seeded into the upper chamber. The lower chambers were then filled with DMEM containing 10% FBS. Following a 24 h incubation at 37°C with 5% CO_2, non-invaded cells were removed using a cotton swab. Invasive cells were fixed with 4% polyoxyethylene, stained with 0.5% crystal violet, washed with PBS and dried in air. Finally, invasive cells were counted in five randomly selected visual fields under an inverted
microscope (magnification, x200; Olympus Corporation, Tokyo, Japan).

**Target prediction.** The TargetScan (http://www.targetscan.org/) and PicTar (http://pictar.mdc-berlin.de/) were used to predict the potential targets of miR-495.

**Luciferase reporter assay.** Bioinformatic analysis indicated a potential miR-495 binding site in the 3'-UTR region of IGF1R. Luciferase reporter plasmids, pMIR-IGF1R-3'-UTR wild-type (Wt) and pMIR-IGF1R-3'-UTR wild mutant (Mut), were chemically synthesized by Shanghai GenePharma Co., Ltd. Cells were seeded into 24-well plates at a density of 1.5x10^5 cells per well. After incubation overnight, cells were co-transfected with the wild-type or mutant 3'-UTR of IGF1R plasmid, and miR-495 mimics or miR-NC using the Lipofectamine 2000 reagent, according to the manufacturer's protocol. After transfection 48 h, the relative luciferase activity was detected using the Dual-Luciferase Reporter assay system (Promega Corporation, Madison, WI, USA), according to the manufacturer's instructions. Renilla luciferase activity served as an internal control. Each assay was performed in 3 replicates and repeated at least three times.

**Western blot analysis.** Total protein was isolated from tissue specimens or cells with Radioimmunoprecipitation assay lysis buffer (Beyotime Institute of Biotechnology, Haimen, China) containing 0.1 mg/ml phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate and 1 mg/ml aprotinin. The concentration of total protein was quantified with BCA assay kit (Beyotime Institute of Biotechnology). Equal amount of protein was separated by 10% SDS-PAGE and electronically transferred onto a polyvinylidene difluoride membrane (EMD Millipore, Billerica MA, USA). After blocking with 5% nonfat milk in TBST for 2 h at room temperature, the membranes were incubated with primary antibodies at 4˚C overnight. The primary antibodies used in this study include mouse anti-human monoclonal IGF1R antibody (sc-81464; 1:1,000 dilution), mouse anti-human monoclonal p-AKT (sc-271966; 1:1,000 dilution), mouse anti-human monoclonal AKT (sc-81434; 1:1,000 dilution), mouse anti-human monoclonal p-ERK (sc-81492; 1:1,000 dilution), mouse anti-human monoclonal ERK (sc-514302; 1:1,000 dilution), mouse anti-human monoclonal GAPDH antibody (sc-47724; 1:1,000 dilution), all from Santa Cruz Biotechnology, Santa Cruz, CA, USA). Subsequent washing three times with TBST, the membranes were probed with goat anti-mouse horseradish peroxidase (HRP)-conjugated secondary antibody (sc-2005; 1:5,000 dilution; Santa Cruz Biotechnology) at room temperature for 2 h. Protein bands were visualized using an enhanced chemiluminescence kit (EMD Millipore), and analyzed using ImageJ 1.49 (National Institutes of Health, Bethesda, MD, USA). GAPDH served as a loading control.

**Statistical analysis.** Data are shown as the mean ± standard error of at least three independent experiments, and analyzed with Student's t-test or one-way analysis of variance. SPSS 17.0 software (SPSS, Inc., Chicago, IL, USA) was used to perform statistical analysis. Spearman's correlation analysis was adopted to investigate the association between miR-495 and IGF1R mRNA expression level in HCC tissues. P<0.05 was considered statistically significant.

**Results**

**miR-495 is downregulated in HCC tissues and cell lines.** To determine the potential roles of miR-495 in HCC, RT-qPCR was performed to detect miR-495 expression levels in 47 primary HCC tissues and matched adjacent non-tumour tissues. P<0.05 compared with matched adjacent non-tumour tissues. (B) miR-495 levels in three HCC cell lines (SMMC-7721, Hep3B and HuH7) and immortalized normal liver epithelial cell line (THLE-3) were examined through RT-qPCR. P<0.05 compared with THLE-3. miR, microRNA; HCC, hepatocellular carcinoma; RT-qPCR, reverse transcription-quantitative polymerase chain reaction.

Low miR-495 expression is correlated with adverse clinical features of patients with HCC. The patients with HCC were subsequently divided into either miR-495 low-expression
Ye et al: miR-495 in Hepatocellular Carcinoma

Table I. Association between miR-495 expression and clinical features of hepatocellular carcinoma patients.

| Clinical features       | Case number | miR-495 expression | P-value |
|-------------------------|-------------|--------------------|---------|
|                         | Low  | High  |         |
| Age                     |      |       |         |
| <60 years               | 20   | 11    | 9       | 0.642  |
| ≥60 years               | 27   | 13    | 14      |        |
| Sex                     |      |       |         |
| Male                    | 31   | 17    | 14      | 0.471  |
| Female                  | 16   | 7     | 9       |        |
| Tumour size             |      |       |         |
| <5 cm                   | 25   | 9     | 16      | 0.028  |
| ≥5 cm                   | 22   | 15    | 7       |        |
| HBsAg                   |      |       |         |
| Negative                | 6    | 4     | 2       | 0.413  |
| Positive                | 41   | 20    | 21      |        |
| TNM stage               |      |       |         |
| I-I-II                  | 22   | 7     | 15      | 0.013  |
| III-IV                  | 25   | 17    | 8       |        |
| Lymph node metastasis   |      |       |         |
| Negative                | 26   | 8     | 18      | 0.011  |
| Positive                | 21   | 16    | 5       |        |
| Differentiated          |      |       |         |
| Well and moderate       | 25   | 14    | 11      | 0.471  |
| Poor                    | 22   | 10    | 12      |        |

*P<0.05. miR, microRNA.

Group (n=24) or miR-495 high expression group (n=23) to elucidate the clinical significance of miR-495 in HCC. The median expression levels of miR-495 in HCC tissues were regarded as cut-off. As shown in Table I, the low miR-495 expression level was correlated with tumour size (P=0.028), tumor-node-metastasis (TNM) stage (P=0.013) and lymph node metastasis (P=0.011). Conversely, miR-495 expression was not correlated with other clinical features, including age (P=0.642), sex (P=0.471), HBsAg (P=0.413), and differentiated (P=0.471). These results implied that miR-495 may be a prognostic indicator for patients with HCC.

miR-495 inhibits cell proliferation and invasion in HCC. Hep3B cells were transfected with miR-495 mimics or miR-NC to examine the effects of miR-495 on the biological characteristics of tumours. Transfection efficiency was determined through RT-qPCR, and the results indicated that miR-495 was markedly upregulated in Hep3B cells transfected with miR-495 mimics (P<0.05; Fig. 2A). CCK-8 assay was conducted to verify the effect of miR-495 overexpression on HCC cell proliferation. In Fig. 2B, upregulation of miR-495 inhibited Hep3B cell proliferation (P<0.05). Cell invasion assay was also performed to show the effect of miR-495 on HCC cell invasion abilities. The results demonstrated that the restored miR-495 expression reduced the invasive capabilities of Hep3B cells (P<0.05; Fig. 2C). These results illustrated the tumour-suppressive effects of miR-495 on HCC cell proliferation and invasion.

IGF1R is a direct downstream target of miR-495 in HCC. To investigate the mechanisms by which miR-495 plays its tumour-suppressing roles in HCC, bioinformatics analysis
was conducted to predict the candidate targets of miR-495. IGF1R, which is highly expressed in HCC and possibly involved in HCC formation and progression (24,25), was predicted as a potential target of miR-495 (Fig. 3A) and consequently selected for further experimental validation. To confirm this hypothesis, we carried out a luciferase reporter assay in Hep3B cells co-transfected with wild-type or mutant 3'-UTR of IGF1R plasmid and miR-495 mimics or miR-NC. In Fig. 3B, ectopic miR-495 expression significantly decreased the luciferase activity of pMIR-IGF1R-3'-UTR Wt in Hep3B cells (P<0.05) but did not affect the luciferase activity of pMIR-IGF1R-3'-UTR Mut. To confirm whether IGF1R is a direct target of miR-495, we performed RT-qPCR and Western blot analysis and then determined the regulatory effects of miR-495 on endogenous IGF1R expression in HCC cells. RT-qPCR and Western blot analysis revealed that the restored miR-495 expression suppressed the IGF1R protein expression, whereas pcDNA3.1-IGF1R co-transfection could rescue the IGF1R expression in Hep3B cells (P<0.05; Fig. 3C). Subsequent functional assays demonstrated that the restored IGF1R expression rescued the suppressive effects of miR-495 on the proliferation (P<0.05; Fig. 5B) and invasion of Hep3B cells. These results implied that miR-495 was negatively associated with the mRNA expression level of IGF1R in HCC tissues (r=-0.6591, P<0.001; Fig. 4C).

IGF1R upregulation rescues the tumour-suppressive roles induced by miR-495 overexpression in HCC. Rescue experiments were performed to confirm whether the biological roles of miR-495 in HCC are mediated by IGF1R. Hep3B cells were transfected with miR-495 mimics with or without IGF1R overexpression plasmid (pcDNA3.1-IGF1R). Western blot analysis indicated that miR-495 overexpression decreased the IGF1R protein expression, whereas pcDNA3.1-IGF1R co-transfection could rescue the IGF1R expression in Hep3B cells (P<0.05; Fig. 5A). Subsequent functional assays demonstrated that the restored IGF1R expression rescued the suppressive effects of miR-495 on the proliferation (P<0.05; Fig. 5B) and invasion of Hep3B cells. These results implied that miR-495 plays its tumour-suppressing roles in HCC partly by downregulating IGF1R.

miR-495 attenuates AKT and ERK signalling pathways in HCC. IGF1R likely performs its functions partly by participating in

Figure 3. IGF1R is a direct downstream target of miR-495 in HCC. (A) Sequence alignment of wild-type and mutated putative miR-495-binding sites in the 3'-UTR of IGF1R. (B) Hep3B cells were transfected with miR-495 mimics or miR-NC, along with wild-type or mutant 3'-UTR of IGF1R plasmid. After 48 h of transfection, luciferase activities were detected using the Dual-Luciferase Reporter Assay system. *P<0.05 compared with miR-NC. (C) RT-qPCR and (D) western blot analysis of the mRNA and protein expression of IGF1R in Hep3B cells transfected with miR-495 mimics or miR-NC, respectively. *P<0.05 compared with miR-NC. IGF1R, insulin-like growth factor receptor-1; miR, microRNA; HCC, hepatocellular carcinoma; 3'-UTR, 3'-untranslated region; miR-NC, miRNA mimics negative control; RT-qPCR, reverse transcription-quantitative polymerase chain reaction.
To determine whether miR-495 is involved in the regulation of AKT and ERK pathways in HCC, we detected the expression levels of AKT, p-AKT, ERK and p-ERK in Hep3B cells transfected with miR-495 mimics or miR-NC. Western blot analysis demonstrated that miR-495 overexpression reduced the expression of p-AKT and p-ERK in Hep3B cells (Fig. 6). Conversely, the expression of total AKT and ERK in these two
cell lines did not significantly change. These results suggested that miR-495 inactivates AKT and ERK signalling pathways in HCC.

**Discussion**

Recently, increasing studies reported that miRNAs are abnormally expressed in various types of human cancers (29-31) and can participate in the tumourigenesis and tumour development of HCC (32-33). miRNA-based targeted therapy is effective against different molecular targets and can increase the sensitisation of cancer cells to therapy by several folds (34). Therefore, further validation of potentially important miRNAs involved in HCC initiation and progression may provide valuable insights into the treatment of patients with HCC. In our study, miR-495 was significantly downregulated in HCC tissues and cell lines. Low miR-495 expression levels were correlated with adverse clinical features of the patients with HCC. The restored expression of miR-495 inhibited the proliferation and invasion of HCC cells in vitro. IGF1R was identified as a direct target of miR-495 in HCC, and miR-495 upregulation attenuated the activation of AKT and ERK signalling pathways in HCC. Therefore, miR-495 might serve as a tumour suppressor in HCC by directly targeting IGF1R and regulating AKT and ERK signalling pathways and might be developed as a novel therapeutic target for the treatment of patients with this fatal malignancy.

miR-495 is aberrantly expressed in numerous types of human cancer. For example, miR-495 is upregulated in bladder cancer tissues and cell lines. High miR-495 expression levels are correlated with tumour size, TNM stage and lymph node metastasis of patients with bladder cancer (18). However, miR-495 in medulloblastoma is downregulated in tumour tissues compared with that in normal cerebellum tissues. Log-rank analysis demonstrated that the average survival time of patients with medulloblastoma and with low miR-495 levels is shorter than that of patients with high miR-495 expression levels. Multivariate analysis also demonstrates miR-495 as an independent predictor of the overall survival of patients with medulloblastoma (35). miR-495 is weakly expressed in prostate cancer and associated with prostate-specific antigen levels, lymph node invasion and Gleason scores (36). miR-495 is also downregulated in osteosarcoma (19), melanoma (20), endometrial cancer (21), acute myeloid leukaemia (22), renal cell carcinoma (37), breast cancer (38,39) and lung cancer (40,41). These findings suggested that miR-495 expression exhibits tissue specificity and may be a biomarker for these human cancers.

miR-495 plays tumour suppressive roles in multiple types of human malignancy. For instance, Jiang et al revealed that miR-495 overexpression suppresses osteosarcoma cell proliferation, colony formation, invasion and increased apoptosis in vitro (19). Studies showed that miR-495 upregulation inhibits cell proliferation and invasion and induces a metabolic shift in glioma (42-44). Formosa et al (36) and Li et al (45) indicated that the restored miR-495 expression attenuates prostate cancer cell growth and metastasis and promotes apoptosis in vitro. Liu et al reported that ectopic miR-495 expression decreases cell proliferation and metastasis and triggers cell apoptosis of melanoma (20). Xu et al demonstrated that miR-495 re-expression represses endometrial cancer cell growth and migration, promotes apoptosis and reduces growth in vivo (21). Lv et al found that restored miR-495 expression inhibits cell proliferation and motility and induces G0/G1 phase arrest in renal cell carcinoma (37). In lung cancer, miR-495 is involved in the regulation of cell proliferation, migration, epithelial-mesenchymal transition, chemosensitivity and chemoresistance (40,41,46). However, Tan et al indicated that miR-495 serves as an oncogene in bladder cancer through the regulation of cell proliferation and invasion (18). These conflicting findings suggested that the functional roles of miR-495 in human malignancies may be multifaceted and mainly dependent on involved tissues and their target genes.

The following target miR-495 genes have been identified: HMGN5 (19) in osteosarcoma; GFI1 (35) in medulloblastoma; Glut1 (42), MYB (43) and CDK6 (44) in glioma; FZD4 (36), Akt (45) and miTOR (45) in prostate cancer; SATB1 (37) in renal cell carcinoma; STAT3 (38) and Bmi-1 (39) in breast cancer; epithelial and endothelial tyrosine kinase (40), MTA3 (41) and ATPTA (46) in lung cancer; and PTEN (18) in bladder cancer. In our study, IGF1R was demonstrated to be a direct functional downstream target of miR-495 in HCC. IGF1R, a transmembrane tyrosine kinase receptor of the insulin receptor family, has been reported to be upregulated in multiple types of cancer, such as osteosarcoma (47), colorectal cancer (48), prostate cancer (49), gastric cancer (50), endometrial cancer (51) and bladder cancer (52). A previous study revealed that IGF1R is significantly upregulated in HCC and correlated with TNM stage. Univariate analysis indicated that high IGF1R expression predicted poor overall and disease-free survival for patients with HCC. In multivariate analysis, IGF1R is significant in the overall survival of patients with HCC (24). Functional experiments demonstrated that IGF1R...
downregulation inhibits HCC cell proliferation and invasion but increases apoptosis (25). Therefore, IGFR1 could be developed as a novel therapeutic target in HCC because of its cancer-related functions.

In conclusion, this study is the first to demonstrate that miR-495 inhibited the proliferation and invasion of HCC cells by directly targeting IGFR1 and regulating AKT and ERK signalling pathways. These results provide novel insights into the molecular mechanism underlying HCC progression and suggest that miR-495 may be investigated as a novel therapeutic target for patients with HCC.

Acknowledgements

The study was supported by grants from Key Disciplines Group Construction Project of Pudong Health Bureau of Shanghai (PWZxq2014-12), Natural Science Foundation of China (no. 81571718), Shanghai Science and Technology Committee Foundation (no. 17ZR1421600), Science and Technology Development Fund of Shanghai Pudong New Area (PKJ2016-Y50) and Talents Training Program of Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine (grant no. QMX2017-01).

References

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108, 2015.
2. El-Serag HB and Rudolph KL: Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2566, 2007.
3. Forner A, Llovet JM and Bruix J: Hepatocellular carcinoma. Lancet 379: 1245-1255, 2012.
4. Yu MC and Yuan JM: Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 127 (Suppl. 1): S72-S78, 2009.
5. Zeng Z: Human genes involved in hepatitis B virus infection. World J Gastroenterol 20: 7696-7706, 2014.
6. Dhanasekaran R, Limaye A and Cabrera R: Hepatocellular carcinoma: Current trends in worldwide epidemiology, risk factors, diagnosis, and therapies. Hepat Med 4: 19-37, 2012.
7. Aravalli RN, Steyer CJ and Creagan EG: Molecular mechanisms of hepatocellular carcinoma. Hepatology 48: 2047-2063, 2008.
8. Kloosterman WP and Plasterk RH: The diverse functions of microRNAs in animal development and disease. Dev Cell 11: 441-450, 2006.
9. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
10. Gu S, Jin L, Zhang F, Sarnow P and Kay MA: Biological basis for restriction of microRNA targets to the 3′ untranslated region in mammalian mRNAs. Nat Struct Mol Biol 16: 144-150, 2009.
11. Yan JJ, Chang Y, Zhang YN, He XX and Huang HJ: miR-195 inhibits cell proliferation via targeting AEG-1 in hepatocellular carcinoma. Oncol Lett 13: 3118-3126, 2017.
12. Pengcheng S, Ziqi W, Luyao Y, Li Z, Yuwei L, Lechen L and Wanhai X: MicroRNA-495 inhibits cell proliferation and invasion via targeting IGF-1R in hepatocellular carcinoma. Carcinogenesis 33: 1126-1137, 2012.
13. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2015. CA Cancer J Clin 70: 769-816, 2015.
14. Gandhi NS, Tekade RK and Chougule MB: Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: Current progress and advances. J Control Release 194: 238-256, 2014.
15. Wang C, Yun Z, Zhao T, Liu X and Ma X: MiR-495 is a predictive biomarker that downregulates GFPI expression in medulloblastoma. Cell Physiol Biochem 36: 1340-1349, 2015.
16. Formosa A, Markert EK, Lena AM, Italiano D, Finazzi-Agro E, Levine AJ, Bernardini S, Garabadguv A, Melino G and Candri E: MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells. Oncogene 33: 5173-5182, 2014.
17. Lv C, Bai Z, Liu Z, Luo P and Zhang J: MicroRNA-495 suppresses human renal cell carcinoma malignancy by targeting SATB1. Am J Transl Res 7: 1992-1999, 2015.
38. Chen Y, Luo D, Tian W, Li Z and Zhang X: Demethylation of miR-495 inhibits cell proliferation, migration and promotes apoptosis by targeting STAT-3 in breast cancer. Oncol Rep 37: 3581-3589, 2017.

39. Wang L, Liu JL, Yu L, Liu XX, Wu HM, Lei FY, Wu S and Wang X: Downregulated miR-495 [Corrected] inhibits the G1-S phase transition by targeting Bmi-1 in breast cancer. Medicine 94: e718, 2015.

40. Wei T, Zhu W, Fang S, Zeng X, Huang J, Yang J, Zhang J and Guo L: miR-495 promotes the chemoresistance of SCLC through the epithelial-mesenchymal transition via Etk/BMX. Am J Cancer Res 7: 628-646, 2017.

41. Chu H, Chen X, Wang H, Du Y, Wang Y, Zang W, Li P, Li J, Chang J, Zhao G and Zhang G: MiR-495 regulates proliferation and migration in NSCLC by targeting MTA3. Tumour Biol 35: 3487-3494, 2014.

42. Nie S, Li K, Huang Y, Hu Q, Gao X and Jie S: miR-495 mediates metabolic shift in glioma cells via targeting Glut1. J Craniofac Surg 26: e155-e158, 2015.

43. Zhang B, Yuan F, Liu J, Li Y, Zhou F, Liu X, Hao Z, Li Q, Zheng Y and Wang W: Hsa-miR-495 acts as a tumor suppressor gene in glioma via the negative regulation of MYB. Mol Med Rep 14: 977-982, 2016.

44. Chen SM, Chen HC, Chen SJ, Huang CY, Chen PY, Wu TW, Feng LY, Tsai HC, Lui TN, Hsueh C and Wei KC: MicroRNA-495 inhibits proliferation of glioblastoma multiforme cells by down-regulating cyclin-dependent kinase 6. World J Surg Oncol 11: 87, 2013.

45. Li JZ, Wang ZL, Xu WH, Li Q, Gao L and Wang ZM: MicroRNA-495 regulates migration and invasion in prostate cancer cells via targeting Akt and mTOR signaling. Cancer Invest 34: 181-188, 2016.

46. Song L, Li Y, Li W, Wu S and Li Z: miR-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of copper-transporting P-type adenosine triphosphatase A (ATP7A). J Cell Biochem 115: 1234-1242, 2014.

47. Wang YH, Han XD, Qiu Y, Xiong J, Yu Y, Wang B, Zhu ZZ, Qian BP, Chen YX, Wang SF, et al: Increased expression of insulin-like growth factor-1 receptor is correlated with tumor metastasis and prognosis in patients with osteosarcoma. J Surg Oncol 105: 235-243, 2012.

48. Shiratsuchi I, Akagi Y, Kawahara A, Kinugasa T, Romeo K, Yoshida T, Ryu Y, Gotanda Y, Kage M and Shirouzu K: Expression of IGF-1 and IGF-1R and their relation to clinicopathological factors in colorectal cancer. Anticancer Res 31: 2541-2545, 2011.

49. Ma Y, Cheng Q, Ren Z, Xu L, Zhao Y, Sun J, Hu S and Xiao W: Induction of IGF-1R expression by EGR-1 facilitates the growth of prostate cancer cells. Cancer Lett 317: 150-156, 2012.

50. Gryko M, Kiśluk J, Cepowicz D, Zińczuk J, Kamocki Z, Guzińska-Ustymowicz K, Pryczynicz A, Czyżewska J, Kemono A and Kędra B: Expression of insulin-like growth factor receptor type 1 correlate with lymphatic metastases in human gastric cancer. Pol J Pathol 65: 133-140, 2014.

51. Pengchong H and Tao H: Expression of IGF-1R, VEGF-C and D2-40 and their correlation with lymph node metastasis in endometrial adenocarcinoma. Eur J Gynaecol Oncol 32: 660-664, 2011.

52. Xie QX, Lin XC, Zhang MF, Han CX and Guo YH: Expression of IGF-1 and IGF-1R in bladder cancer. Ai Zheng 23: 707-709, 2004 (In Chinese).